Select a category

GoDaddy (GDDY) shares surged Friday, a day after the company raised its 2024 revenue guidance after the bell.

The internet domain company now expects full-year revenue of between $4.525 billion and $4.565 billion, up from its prior range of $4.50 billion to $4.56 billion and representing year-over-year growth of about 7% at the midpoint.

In the second quarter, GoDaddy posted earnings per share (EPS) of $1.01 on revenue of $1.12 billion, roughly in line with consensus expectations of analysts polled by Visible Alpha. Total bookings were $1.26 billion, up 11% year-over-year.

"We are making progress on our key initiatives, including growing discovery and engagement of our AI-powered experience, GoDaddy Airo," Chief Executive Officer (CEO) Aman Bhutani said. 

Shares of GoDaddy climbed more than 6% to $150.54 as of 2 p.m. ET Friday. They have gained about 42% this year.

Read more on Investopedia

U.S. equities cratered at midday Friday after the government reported fewer jobs were created in July than expected, raising concerns about the strength of the U.S. economy. The Dow and S&P 500 lost about 2%, and the Nasdaq sank nearly 3%.

Intel (INTC) shares plunged after the chipmaker reported a wider-than-expected loss and announced it would slash 15% of its workforce in an effort to cut costs. The news dragged down other semiconductor stocks as well.

Amazon (AMZN) shares sank as the online retailer’s revenue and guidance were short of forecasts on weaker-than-anticipated consumer purchases.

Shares of Snap (SNAP) plummeted after the operator of the Snapchat social media platform also posted revenue and guidance that missed expectations, citing a softer advertising environment. 

Apple (AAPL) shares were higher after the iPhone maker's iPad sales and services revenue jumped.

Shares of GoDaddy (GDDY) advanced as the internet domain registrar beat sales estimates and boosted its outlook, citing strong demand.

Clorox (CLX) shares rose after the cleaning products maker exceeded earnings expectations on higher prices and cost cuts. 

Oil and gold futures dropped. The yield on the 10-year Treasury note tumbled. The U.S. dollar lost ground to the euro, pound, and yen. Prices for most major cryptocurrencies fell. 

Read more on Investopedia

Shares of Spirit Airlines (SAVE) fell further Friday, a day after the budget airline said it would furlough about 240 pilots and reported a wider-than-forecast quarterly loss.

Spirit on Thursday posted a $192.9 million second-quarter loss, far larger than the $2.3 million loss in the prior-year period, and said the furloughs would take effect starting Sept. 1. Shares closed more than 8% lower and were down a further 3% to $2.69 as of 10:45 a.m. ET Friday.

Smaller airlines like Spirit have been struggling with soaring costs in a domestic airline industry dominated by four big players: American Airlines (AAL), Delta Air Lines (DAL), Southwest Airlines (LUV), and United Airlines (UAL). Last week, Southwest said it would abandon its longtime policy of open seating in an effort to "increase revenue opportunities" amid pressure from activist investor Elliott Investment Management.

A $3.8 billion merger with rival JetBlue (JBLU) that would have given Spirit more heft was called off in March after a federal judge blocked the deal.  

Earlier this week, Spirit announced plans to offer more premium services as it aims to boost revenue.

Read more on Investopedia

Global chip stocks tumbled Friday after Intel's (INTC) layoffs plan and fears of overspending on artificial intelligence (AI) by the tech industry unnerved investors.

Intel shares are plunging 24% in premarket trading on the back of a litany of bad news. The chipmaker reported everything from a wider-than-expected second-quarter loss to a grim growth forecast, a dividend halt plan, and a $10 billion turnaround that includes cutting 15% of its workforce.

Shares of Dutch semiconductor-gear maker ASML Holding (ASML) are falling 6%, and American depositary receipts (ADRs) of British chip designer Arm Holdings (ARM) and Taiwan Semiconductor Manufacturing Company (TSM), the world’s largest contract chip maker, are both dropping 5%.

In Japanese trading Friday, Tokyo Electron, which makes etching machines for semiconductor factories, closed 12% lower and Arm majority owner SoftBank Group fell 8%.

Amazon (AMZN) shares are falling about 10% in premarket trading after the tech titan's third-quarter revenue outlook fell short of analysts' estimates and ramped up spending on AI initiatives. Amazon spent $17.62 billion in Q2 purchases of property and equipment, a 54% jump from a year ago.

Apart from Facebook parent Meta Platforms (META), investors have sold off the delivery giant's Magnificent Seven peers like Microsoft (MSFT) and Google parent Alphabet (GOOGL) for perceived overspending on the technology and sparked a tech selloff. Meanwhile, another AI investor favorite, Nvidia (NVDA), is down 5%.

Read more on Investopedia

Outrage as #EndBadGovernance protesters refused to be patriotic and responsible citizens while ventilating their ang3r.

The protesters were seen putting a casket with the picture of the president on a tricycle in the course of the protest.

Continue reading on Instablog

Novo Nordisk (NVO) is set to report earnings for the second quarter on Wednesday morning after a first half in which the company's market of potential customers for its Ozempic and Wegovy weight-loss drugs expanded.

Analysts project that Novo Nordisk's drugs will help lift the Danish drugmaker's revenue and income. Analyst estimates compiled by Visible Alpha project Novo Nordisk will report a year-over-year jump of about 26% in revenue to 68.47 billion Danish kroner ($9.9 billion), with a rise of nearly 10% in profit to 21.27 billion kroner ($3.08 billion).

In the first quarter, Novo Nordisk said sales of Ozempic and Wegovy rose 25% year over year and said that demand would likely continue to outpace supply for the rest of 2024.

The weight-loss drug sales led Novo Nordisk to lift its guidance for the year, projecting revenue growth between 19% to 27%, slightly up from a previous projection of 18% to 26%.

Investors could expect that guidance to rise again when the company reports Wednesday. Novo Nordisk said in May that its updated figures included expectations that the drugs would face supply constraints over the course of 2024, and that revenue could grow further depending on the company's investments in production capacity.

Novo Nordisk and Eli Lilly (LLY) have both said that the booming popularity of their weight-loss drugs has meant their supply will likely lag demand as they work to increase production. For its part, Novo Nordisk has made acquisitions and investments to bolster its production capabilities for the drugs, including a $4.1 billion plan to expand its facilities in North Carolina by 2029.

Ozempic and Wegovy also have been introduced to new markets like China over the first half of the year and studies over the last year have also led regulators to support updating the drugs' labels to include evidence that they can have positive cardiovascular impacts along with their weight-loss benefits.

Wegovy also has received approval to start being sold in Australia, further expanding the drug's market, reported Thursday.

American depositary receipts (ADRs) of Novo Nordisk finished Thursday roughly flat and about 28% above where they started the year.

Read more on Investopedia